Novo Nordisk A/S accomplished a landmark fourth-quarter performance in 2023, surpassing the Zacks Consensus Estimate with reported earnings of 71 cents per American Depositary Receipt (ADR). This remarkable figure soared past last year’s 41 cents per ADR. Revenues reached $9.51 billion, marking a striking 37% increase in Danish kroner (DKK) and a 43% surge at constant exchange rates (CER) for the reported quarter. Unquestionably, this outstanding performance outperformed the Zacks Consensus Estimate of $9.14 billion. This impressive growth was primarily propelled by elevated sales in Diabetes and Obesity Care, powered by a substantial upswing in GLP-1 product sales, albeit partially offset by a decrement in insulin and Rare disease sales.

Market Triumph

Novo Nordisk shares experienced a remarkable 56.8% rally in the past year, overshadowing the industry’s 20% growth.

Image Source: Zacks Investment Research

All growth rates cited are on a year-over-year basis and at CER.

Breaking Down the Quarter

Novo Nordisk operates within two principal segments: Diabetes and Obesity Care, and Rare disease.

The Diabetes and Obesity Care segment exhibited sales of DKK 61.3 billion in the fourth quarter of 2023, reflecting a substantial 48% surge. Noteworthy sales increases were witnessed in several categories, with Ozempic ascendant, attaining sales of DKK 30.1 billion, an impressive 85% surge. Additionally, Rybelsus saw its sales soar to DKK 5.9 billion, marking a formidable 51% elevation. Meanwhile, Obesity Care sales, including Saxenda and Wegovy, skyrocketed by an astonishing 114% year over year.

Sales in the Rare disease segment experienced a marginal decline of 5% to DKK 4.6 billion in the fourth quarter of 2023. Notably, sales of rare blood disorder products leaped by 4%, while sales of hemophilia A products receded by 19%. On the flip side, there was a substantial 50% upsurge in sales of Hemophilia B products, and NovoSeven sales rose by 6% to DKK 2 billion.

Sales and distribution costs mounted by 25% in DKK and ascended by 29% at CER year over year in the reported quarter. This upswing was attributed to promotional activities in North America and International markets related to Ozempic and Rybelsus, in addition to Obesity care market development activities, albeit partially offset by adjustments to legal provisions.

Simultaneously, research and development costs escalated by 29% in DKK and hiked by 32% at CER from the year-ago quarter’s figures. This upsurge stemmed from heightened clinical activity for late-stage studies and amplified research activities, offset in part by expenses avoided subsequent to the termination of the development of belcesiran.

Annual Performance and Forward Outlook

For the entirety of 2023, Novo Nordisk recorded sales of $33.69 billion, marking a substantial 36% escalation at CER from the previous year’s figures. This commendable sales figure comfortably exceeded the Zacks Consensus Estimate of $33.44 billion. Furthermore, the company reported full-year earnings of $2.7 per ADR, surpassing the Zacks Consensus Estimate of $2.67.

Novo Nordisk A/S price-consensus-eps-surprise-chart | Novo Nordisk A/S Quote

Novo Nordisk’s sales are projected to grow between 18-26% at CER in 2024, with operating profit expected to surge by 21-29% at CER. These indicative forecasts suggest a stable trajectory for sales growth in North America and International Operations, primarily driven by the volume surge of GLP-1-based Diabetes and Obesity care products. The company is placing great stock in this segment, particularly banking on the success of Ozempic in the U.S. market and Wegovy in the obesity care market following its relaunch. However, concerns loom around Wegovy’s restricted roll-out in international markets, and the company foresees intermittent supply constraints. The company recently commenced a gradual escalation of the supply of lower dose strengths of Wegovy in the United States to meet the escalating demand.

Strategic Analysis and Future Optimism

Novo Nordisk’s exceptional performance in the fourth quarter of 2023, mainly propelled by soaring Diabetes and Obesity Care sales, has surpassed expectations. The remarkable market traction experienced by Ozempic and Rybelsus since their launches is poised to fuel future growth. The robust uptake of Wegovy thus far signifies a significant contribution to the company’s revenue stream. Moreover, Novo Nordisk is actively expanding Wegovy’s supply capacity, post its relaunch, not only in the United States but also in other geographies, reaffirming a promising crescendo in revenue generation in the upcoming quarters.

Industry Landscape and Stock Recommendations

Novo Nordisk presently boasts a Zacks Rank #1 (Strong Buy). Other notable top-ranked stocks in the drug and biotech industry include Puma Biotechnology, Inc. (PBYI), ADMA Biologics (ADMA), and Journey Medical (DERM), each currently holding a Zacks Rank #1. Notably, the Zacks Consensus Estimate for Puma Biotech’s 2023 and 2024 earnings per share (EPS) has remained constant at 73 cents and 69 cents, respectively.

Puma Biotech’s shares have soared by 9.5% over the past year, exhibiting robust performance, with a four-quarter average earnings surprise of 76.55%. Such consistent positive performance is truly commendable and sets a promising tone for the industry as a whole.